{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:13:29Z","timestamp":1793841209152,"version":"4.6.1"},"reference-count":77,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100003478","name":"ministry of health, labour and welfare","doi-asserted-by":"publisher","award":["20FC1030"],"award-info":[{"award-number":["20FC1030"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune astrocytopathy characterized by autoantibodies against aquaporin-4 (AQP) that predominantly affecting women of childbearing potential. Unlike multiple sclerosis, NMOSD poses a higher risk of severe and irreversible postpartum relapse, making pregnancy a significant concern in affected women. Historically, in Japan, immunosuppressive treatments were contraindicated in women who could become pregnant, leading many to discontinue therapy before conception. This often resulted in relapse and sometimes required pregnancy termination or abandonment. At present, immunosuppressants such as azathioprine, tacrolimus, and cyclosporine are considered beneficial during pregnancy. Five monoclonal antibody therapies have now been approved and are covered by national insurance for the treatment of NMOSD. These developments have expanded treatment options, enabling safer pregnancies and allowing more women with NMOSD to consider childbirth. To ensure optimal outcomes, individualized, evidence-based treatment plans are essential. Shared decision-making between patients and healthcare providers is critical, particularly when evaluating the safety of monoclonal antibody therapies during pregnancy and their potential impact on fetal development. This review outlines recent insights into the impact of NMOSD on patients of childbearing age, including family planning, postpartum management, and breastfeeding. It emphasizes the importance of balancing disease control with reproductive goals through informed and collaborative care strategies that also encompass AQP4-antibody\u2013negative NMOSD and myelin oligodendrocyte glycoprotein antibody-associated disease.<\/jats:p>","DOI":"10.1177\/17562864251384504","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:08:16Z","timestamp":1761566896000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Progress in the management of pregnancy in patients with neuromyelitis optica spectrum disorder"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1903-1400","authenticated-orcid":false,"given":"Yuko","family":"Shimizu","sequence":"first","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University, Kawada-cho 8-1, Shinjuku-ku, Tokyo 162-8666, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1197-1705","authenticated-orcid":false,"given":"Ryotaro","family":"Ikeguchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University, Shinjuku-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3096-4156","authenticated-orcid":false,"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[{"name":"Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine, Fukushima, Japan"},{"name":"Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7711-3466","authenticated-orcid":false,"given":"Kenichi","family":"Todo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University, Shinjuku-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104760"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31824c466f"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318250d812"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515583376"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-0313-y"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004681"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301483"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-820683-6.00013-0"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.7.964"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103499"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002208"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011744"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00501"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181ea9f15"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104627"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-7031-y"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.544434"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13167-018-0143-9"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221130934"},{"key":"e_1_3_4_21_2","unstructured":"National Center for Child Heath and Development. https:\/\/www.ncchd.go.jp\/hospital\/about\/section\/preconception\/ (accessed 25 August 2025)."},{"key":"e_1_3_4_22_2","first-page":"993","article-title":"Pharmacokinetics and safety evaluation of medications during pregnancy and lactation","volume":"75","author":"Fujioka I","year":"2023","unstructured":"Fujioka I, Murashima A. Pharmacokinetics and safety evaluation of medications during pregnancy and lactation. Brain Nerve 2023; 75: 993\u2013998. (in Japanese)","journal-title":"Brain Nerve"},{"key":"e_1_3_4_23_2","unstructured":"Obstetrics practice guidelines. In: The Japan Society of Obstetrics and Gynecology (JSOG) (ed.) Obstetrics edition. Japan Association of Obstetricians and Gynecologists (JAOG) (In Japanese). https:\/\/www.jsog.or.jp\/activity\/pdf\/gl_sanka_2023.pdf (2023 accessed 25 August 2025)."},{"key":"e_1_3_4_24_2","unstructured":"Drugs and lactation database (LactMed\u00ae) https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501922\/ (2024 accessed 25 August 2025)."},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-018-0517-z"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1159\/000511957"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01920"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/cen3.12784"},{"key":"e_1_3_4_29_2","unstructured":"Eculizumab (recombinant) Soliris\u00ae Anti-complement (C5) monoclonal antibody preparations Package Insert https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/870056_6399424A1023_1_22 (2025 accessed 25 August 2025)."},{"key":"e_1_3_4_30_2","unstructured":"Soliris\u00ae (eculizumab) https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/soliris-epar-product-information_en.pdf (2023 accessed 25 August 2025)."},{"key":"e_1_3_4_31_2","unstructured":"Soliris\u00ae (eculizumab). FDA Pregnancy Category C https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125166s446lbl.pdf(2024 accessed 25 August 2025)."},{"key":"e_1_3_4_32_2","unstructured":"Ravulizumab (genetically modified) Yurtmyris\u00ae Anti-complement (C5) monoclonal antibody preparations. Package Insert https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/870056_6399427A2023_1_02 (2025 accessed 25 August 2025)."},{"key":"e_1_3_4_33_2","unstructured":"Ultomiris\u00ae (ravulizumab-cwvz) injection https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ultomiris-epar-product-information_en.pdf (2025 accessed 25 August 2025)."},{"key":"e_1_3_4_34_2","unstructured":"Ultomiris\u00ae (ravulizumab-cwvz) injection https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761108s023lbl.pdf (2022 accessed 25 August 2025)."},{"key":"e_1_3_4_35_2","unstructured":"Soliris\u00ae (eculizumab) https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501921\/ (2024 accessed 25 August 2025)."},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1502950"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-1946-x"},{"key":"e_1_3_4_38_2","unstructured":"Ravulizumab https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK536687\/ (2025 accessed 25 August 2025)."},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1322412"},{"key":"e_1_3_4_40_2","article-title":"Successful childbirth during satralizumab treatment in neuromyelitis optica spectrum disorder","volume":"16","author":"Nakashima S","year":"2024","unstructured":"Nakashima S, Hao A, Uchio N, et al. Successful childbirth during satralizumab treatment in neuromyelitis optica spectrum disorder. Cureus 2024; 16: e55010.","journal-title":"Cureus"},{"key":"e_1_3_4_41_2","unstructured":"Satralizumab (recombinant) Enspryng\u00ae Package Insert https:\/\/chugai-pharm.jp\/product\/ens\/sc_a\/pi\/#HDR_Warningscg (2025 accessed 25 August 2025)."},{"key":"e_1_3_4_42_2","unstructured":"Enspryng\u00ae (satralizumab-mwge) https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/enspryng-epar-product-information_en.pdf (2025 accessed 25 August 2025)."},{"key":"e_1_3_4_43_2","unstructured":"Enspryng\u00ae (satralizumab-mwge) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761149s000lbl.pdf (2020 accessed 25 August 2025)."},{"key":"e_1_3_4_44_2","unstructured":"Enspryng\u00ae (satralizumab-mwge) https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK565967\/ (2024 accessed 25 August 2025)."},{"key":"e_1_3_4_45_2","unstructured":"Inebilizumab (genetically modified) Yuprizna\u00ae Anti-CD19 monoclonal antibody preparations Package Insert https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00069372.pdf (2024 accessed 25 August 2025). Revised in March 2024."},{"key":"e_1_3_4_46_2","unstructured":"Uplizna\u00ae (inebilizumab) https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/uplizna-epar-product-information_en.pdf (accessed 25 August 2025)."},{"key":"e_1_3_4_47_2","unstructured":"Uplizna\u00ae (inebilizumab) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761142s000lbl.pdf (2020 accessed 25 August 2025)."},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-021-00667-3"},{"key":"e_1_3_4_49_2","unstructured":"Rituximab (genetically modified) Rituxan\u00ae Anti-CD20 monoclonal antibody. Package Insert https:\/\/chugai-pharm.jp\/product\/rit\/div\/pi\/#HDR_Warningscg (2025 accessed 25 August 2025)."},{"key":"e_1_3_4_50_2","unstructured":"Rituxan\u00ae (rituximab) https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mabthera-epar-product-information_en.pdf (2025 accessed 25 August 2025)."},{"key":"e_1_3_4_51_2","unstructured":"Rituxan\u00ae (rituximab) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103705s5464lbl.pdf (2021 accessed 25 August 2025)."},{"key":"e_1_3_4_52_2","unstructured":"(rituximab) https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501798\/ (2025 accessed 25 August 2025)."},{"key":"e_1_3_4_53_2","article-title":"Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: a case-series study","volume":"12","author":"Seyed AM","year":"2021","unstructured":"Seyed AM, Sahraian MA, Shaygannejad V, et al. Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: a case-series study. J Intern Med 2021; 12(Suppl. 2): S491\u2013S494.","journal-title":"J Intern Med"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/EJA.0b013e3283350c54"},{"key":"e_1_3_4_55_2","first-page":"371","article-title":"Neuromyelitis optica after a spinal anaesthesia with bupivacaine","volume":"21","author":"Hosseini H","year":"2012","unstructured":"Hosseini H, Brugieres P, Degos JD, et al. Neuromyelitis optica after a spinal anaesthesia with bupivacaine. Mult Scler 2012; 21: 371\u2013375.","journal-title":"Mult Scler"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2019.03.057"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.2001.1968-2.x"},{"key":"e_1_3_4_58_2","first-page":"2404756","article-title":"Epidural labor analgesia for a patient with neuromyelitis optica: a case report and review of the literature","volume":"2018","author":"Chang A","year":"2018","unstructured":"Chang A, Chung B, Vandse R. Epidural labor analgesia for a patient with neuromyelitis optica: a case report and review of the literature. Case Rep Anesthesiol 2018; 2018: 2404756.","journal-title":"Case Rep Anesthesiol"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1213\/XAA.0000000000000016"},{"key":"e_1_3_4_60_2","article-title":"Epidural anesthesia for neuromyelitis optica in obstetrics: a case report and literature review","volume":"16","author":"Tympa Grigoriadou A","year":"2024","unstructured":"Tympa Grigoriadou A, Asimakopoulos T, Orfanou C, et al. Epidural anesthesia for neuromyelitis optica in obstetrics: a case report and literature review. Cureus 2024; 16: e54966.","journal-title":"Cureus"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1191\/096120399678847696"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.5692\/clinicalneurol.50.27"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-008-0918-7"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2011.05.016"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2016.11.054"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2018-002060"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21468"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S485822"},{"key":"e_1_3_4_69_2","article-title":"Intravenous immunoglobulin treatment during pregnancy and the post-partum period in women with multiple sclerosis: a prospective analysis","volume":"9","author":"Menascu S","year":"2023","unstructured":"Menascu S, Siegel-Kirshenbaum M, Dreyer-Alster S, et al. Intravenous immunoglobulin treatment during pregnancy and the post-partum period in women with multiple sclerosis: a prospective analysis. Mult Scler J Exp Transl Clin 2023; 9: 20552173221151127.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00095-8"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-004-2583-y"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00218-0"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00431-8"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0718-0"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221134214"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209706"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10026-y"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1111\/cen3.12630"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251384504","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864251384504","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251384504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:26:08Z","timestamp":1761747968000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864251384504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":77,"alternative-id":["10.1177\/17562864251384504"],"URL":"https:\/\/doi.org\/10.1177\/17562864251384504","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"17562864251384504"}}